Dr. John Oertle of Envita Medical Centers Underlines the Transformative Role of Precision Medicine on the 'Rising Tides' Podcast
Patients with life-threatening diseases, such as cancer, or other chronic and autoimmune conditions may greatly enhance their chances of positive outcomes if their treatment is personalized to target the root causes of their disease. “There's more data that can be utilized to make better healthcare decisions for you and your family,” said Dr. John Oertle, Chief Medical Officer of Envita Medical Centers. Speaking to Corey Durbin, CEO of SHARx, and Paul Pruitt, Chief Growth Officer of SHARx, on the 'Rising Tides' podcast, Dr. Oertle explained that following this advanced precision medicine approach has led to outstanding patient outcomes.
“We have published a paper on terminal cancer patients indicating that we have 35 times better outcomes than the standard of care,” said Dr. Oertle*. He added that the reason behind this success lies in Envita's innovative precision integrative oncology approach, which has helped many late-stage cancer patients achieve lasting outcomes. Precision medicine is not a one-size-fits-all approach; instead, it involves a deep dive into individual data, including biomarkers, genomics, transcriptomics, metabolism, immune system function, and many other factors. The scope of precision medicine goes beyond oncology, and the Envita team aims to utilize its full potential by proactively treating and preventing various diseases.
Team Envita's goal is to enhance the quality of life while reducing healthcare costs for Americans, and the partnership with SHARx is aimed at working toward this goal. To learn more about how this strategic partnership can help you access the benefits of precision medicine and significantly improve your health, watch this podcast here.
*https://www.scirp.org/journal/paperinformation?paperid=132493
